SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community debates its valuation and future growth prospects following recent earnings and analyst target adjustments. Discussions center around the company's AI projects, particularly Optimus, and whether near-term EV business challenges can bridge to long-term potential. Some traders are betting on a continued rally, while others anticipate a pullback, creating volatility.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid speculation that the U.S. government might take equity stakes in quantum computing companies, though some sources refute active negotiations. Community discussions revolve around the potential implications of government funding and whether this signals long-term growth or a short-term pump. Bullish investors believe this move would validate quantum computing's future, while bears express concerns about overvaluation and the source of the news.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around OG memes and a vision for a culture-driven movement, rather than hype. Discussions emphasize community strength, conviction, and a return to the spirit of 2021 in the crypto space. The community buzzes with anticipation for a potential "moonshot" event and upcoming spaces.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending amid reports and speculation around potential government equity stakes in quantum computing firms, sparking debates about the long-term implications and strategic importance of these investments. Community members are weighing the significance of potential deals versus existing funding, while also discussing the volatile price action and potential for a short squeeze. The broader context involves the race for quantum supremacy and the potential for government involvement in frontier technologies.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending amid reports and speculation regarding potential U.S. government funding and even an equity stake in quantum computing firms. Community discussions revolve around the validity and impact of these reports, with some skeptical about the size and implications of any potential deal, while others see it as a bullish sign of government support for the sector. The stock's movement is also being heavily debated, with both bulls and bears presenting their arguments.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amid reports of potential U.S. government equity stakes in quantum computing firms, sparking excitement and debate within the community. While some welcome the potential government backing as a sign of long-term growth for the sector, others express skepticism, citing concerns about the size of the investment and potential government influence.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer's stock is trending downwards amidst concerns about potential profit warnings following a recent business update. The community is focused on the CFO's performance and the company's revenue forecasting accuracy. Despite design wins and strong AI demand, some investors worry about order delivery timing and the company's ability to meet financial targets.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending as investors assess its operational momentum, particularly in hybrid cloud and AI, following recent Q3 results. The community is discussing its reinvention as an AI player and comparing it to other tech giants like Tesla and Netflix. A key point of interest is the company's infrastructure and automation growth, as well as its progress in quantum computing.

Integer Holdings Corp. engages in the manufacture and development of medical devices and components. The firm has the following product lines: Cardio and Vascular, Cardiac Rhythm Management and Neuromodulation, and Other Markets. The company was founded by Wilson Greatbatch in 1970 and is headquartered in Plano, TX.

Integer Holdings Corp

Integer Holdings is trending as the stock experiences a significant drop following weaker-than-expected financial guidance for 2025 and preliminary guidance for 2026. The community is actively discussing whether the selloff is an overreaction and if $ITGR presents a short squeeze or swing trade opportunity, with some expressing concerns about the company's debt and others seeing a buying opportunity.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences is trending following positive Phase 2 data for their oral anti-inflammatory drug, VTX3232, which showed a significant reduction in a key heart disease marker. The community is buzzing about the potential of this breakthrough to revolutionize cardiovascular treatment and speculating about a possible acquisition by a major pharmaceutical company. Bullish sentiment prevails, with many anticipating further price increases and analysts suggesting high price targets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of...

NVS Reports Positive Late-Stage Data on Kidney Disease Drug 

Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline 

Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.

Shares of Tourmaline Bio (TRML) jumped 58% in the pre-market session on Tuesday after Novartis (NVS) announced that it has agreed to acquire the smaller biopharmaceutical firm.Under the <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-acquire-tourmaline-bio-complementing-cardiovascular-pipeline-pacibekitug-treatment-atherosclerotic-cardiovascular-disease-ascvd">deal</a>, Novartis will commence a tender offer to purchase all outstanding shares of Tourmaline common stock through an indirect wholly owned unit. The deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price and values the company at about $1.4 billion on a fully diluted basis. Following the closing of the tender offer, the unit will merge with Tourmaline, and the company will become an indirect wholly owned subsidiary of Novartis.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TRML">TRML stock</a> jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/NVS">NVS stock</a> fell from ‘Neutral’ to ‘Bearish territory, while message volume rose from ‘low’ to ‘normal’ levels.Novartis stated that the acquisition includes Tourmaline’s Pacibekitug being developed as a treatment option for atherosclerotic cardiovascular disease or the build-up of fats, cholesterol, and other substances in and on the artery walls. Pacibekitug complements Novartis’ cardiovascular strategy, the company said, while noting that with mid-stage trials of Pacibekitug already well-advanced, the company will acquire a late-stage-ready asset."Inflammation is a major driver of cardiovascular disease, and the team at Tourmaline has made significant progress with this asset. We are excited to bring Pacibekitug into the Novartis portfolio and collaborate with the Tourmaline team to advance its development as we diversify our efforts in cardiovascular care," said Shreeram Aradhye, Chief Medical Officer of Novartis. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; The transaction has been unanimously approved by the Board of Directors of both companies. It is expected to close in the fourth quarter of 2025, subject to the satisfaction or waiver of customary closing conditions. Until the transaction is closed, the two companies will continue to operate as separate, independent entities, Novartis said.TRML stock is up by 49% this year, while NVS stock gained over 32%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-launches-ai-machine-learning-platform-called-tunelab/chwKTzARdsU">Eli Lilly Launches AI, Machine Learning Platform Called TuneLab For Biotech Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened

Novartis has announced that it has agreed to acquire the biopharmaceutical firm, and the deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price. 

Equity

Novartis has announced that it has agreed to acquire the biopharmaceutical firm, and the deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price. 


Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's  What You Should Know

The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Tourmaline Bio (TRML) Receives a Buy from Piper Sandler

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Tourmaline Bio (TRML Research Report), with a price targ...

The Lustgarten Foundation Appoints Two New Board Members

The Lustgarten Foundation Appoints Two New Board Members The Lustgarten Foundation Appoints Two New Board Members PR Newswire WOODBURY, N.Y., June 13, 2024 Richard Barakat, MD, and Aaron Kantoff join...

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of...

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $55.60 Consensus Target Price from Analysts

Shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have earned an average recommendation of "Buy" from the six analysts that are currently covering the firm, Marketbeat reports. Six...

Tourmaline Bio (NASDAQ:TRML) Price Target Increased to $72.00 by Analysts at Jefferies Financial Group

Tourmaline Bio (NASDAQ:TRML  Free Report) had its target price raised by Jefferies Financial Group from $41.00 to $72.00 in a report released on Wednesday morning, Benzinga reports. Jefferies...

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.

TRML
Tourmaline Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TRML News

TRMLTourmaline Bio Inc